On this page
Back to topEikon Therapeutics EIKN
Eikon Therapeutics listed on Nasdaq on 5 Feb 2026 and is not in the S&P 500. It is worth $258 million. Its price history starts on 6 Feb 2026. Its board has 7 directors, 3 of them independent. 4 other officers are on file. At 30 Jun 2026, Fidelity (FMR) was its largest institutional holder, with 9.2% of the company.
- Chair and CEO
- Roger M. Perlmutter
- Listed
- 5 Feb 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Millbrae, CA
- Market cap
- $258M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Eikon Therapeutics' market cap since February 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $320M |
Download Eikon Therapeutics' data as JSON, with the weekly market caps in billions of dollars from 6 Feb 2026.
Board and leadership
Board and officers
4 people here also hold roles at other S&P 500 companies.
Board from the proxy filed 30 Mar 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (7) | |||||
| Roger M. PerlmutterChair; Chief Executive Officer and DirectorNot independent 路 since 2021 | |||||
| Leon ChenDirectorNot independent 路 since 2019 路 Audit, CompensationPartner, The Column Group | |||||
| Ma. Fatima FranciscoDirectorAlso at HP and Procter & Gamble | |||||
| Kenneth C. FrazierDirectorIndependent 路 since 2022Chairman of Health Assurance initiatives, General Catalyst | |||||
| Robert Luther HuffinesDirectorIndependent 路 since 2023 路 Audit, Compensation (chair)Retired Global Chairman of Investment Banking, J.P. Morgan Chase & Co.Also at Becton Dickinson and Insulet | |||||
| David W. MelineDirectorIndependent 路 Audit (chair), CompensationFormer Chief Financial Officer, Moderna Inc.Also at HPOther boards: Lonza Group AG and ABB Ltd. | |||||
| Joshua WolfeDirectorNot independent 路 since 2022Co-founder, Lux Capital | |||||
| Officers (4) | |||||
| Alfred Lloyd Bowie Jr.Chief Financial OfficerLast filed 4 Mar 2026 | |||||
| Roy D. BaynesChief Medical OfficerLast filed 4 Mar 2026 | |||||
| Michael A. KlobucharChief Operating OfficerAlso at RevvityLast filed 4 Mar 2026 | |||||
| Benjamin Bruno ThornerGeneral Counsel and Chief Business OfficerLast filed 4 Mar 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of Eikon Therapeutics. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $12.0 million in 2 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 4 Feb 2026Buy | Josh WolfeDirector | $10.0M |
| 4 Feb 2026Buy | Kenneth C. FrazierDirector | $2.0M |
Workforce and hiring
WARN layoff notices
Notices filed under Eikon Therapeutics' own name or a subsidiary's listed in its 10-K.
Notices from 19 Nov 2023 to 19 Nov 2026
Eikon Therapeutics filed 1 notice covering 55 workers since November 2023.
| Notice | Place | Workers |
|---|---|---|
| 21 May 2025 | Millbrae, CA | 55 |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
2 departures and 1 appointment of directors and officers and WARN layoff notices on 1 day in the last two years.
Events, newest first
- 31 Jul 2026 Joshua Wolfe resignedDirector
- 31 Jul 2026 Leon Chen resignedDirector
- 5 Jun 2026 Ma. Fatima D. Francisco appointedClass I director, effective 15 Jun 2026
- 21 May 2025 55 workers in Millbrae, CAWARN notice, effective 21 Jul 2025
Not on file: no trades disclosed by members of Congress or officials since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.